Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al

Ann Oncol. 2016 Feb;27(2):364-5. doi: 10.1093/annonc/mdv549. Epub 2015 Nov 16.

¹ Department of Dermatology and Research Unit EA 4340 'Biomarkers in Cancerology and in Hemato-oncology', AP-HP Ambroise Paré Hospital and University of Versailles-Saint-Quentin-en-Yvelines, Boulogne-Billancourt.
² Department of Toxicology, AP-HP Raymond Poincaré Hospital and University of Versailles-Saint-Quentin-en-Yvelines, Garches.
³ Department of Public Health, AP-HP Ambroise Paré Hospital and University of Versailles-Saint-Quentin-en-Yvelines, Boulogne-Billancourt.
⁴ Department of Pharmacology and CIC-1421, AP-HP, Pitié-Salpêtrière Hospital, Paris INSERM, CIC-1421 and UMR ICAN 1166, Paris Faculty of Medicine, Sorbonne Universités, UPMC Univ Paris 06, Paris, France christian.funck-brentano@upmc.fr.

No abstract available

Publication types